A landmark cardiovascular outcomes trial has demonstrated that GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) reduce the risk of heart attack, stroke, and cardiovascular death by 20% in overweight patients, independent of weight loss effects.
The SELECT trial follow-up data, presented at the American College of Cardiology annual meeting, showed sustained cardiovascular benefits over a 4-year period. The protection was observed even in patients who lost minimal weight, suggesting direct cardiovascular mechanisms.
The findings are reshaping how cardiologists approach prevention. "This puts GLP-1 drugs alongside statins as foundational cardiovascular medications," says Dr. Steven Nissen of the Cleveland Clinic. Insurance coverage for these medications is expected to expand significantly.
Medicare has announced it will cover GLP-1 medications for cardiovascular risk reduction in patients with established heart disease, a major policy shift. The expanded coverage could benefit 10 million Medicare beneficiaries.
Cost remains a barrier for many patients. Brand-name GLP-1 medications cost over $1,000 per month, though generic versions are expected to enter the market by 2028. Pharmaceutical companies are also developing oral formulations that could reduce costs.
